Overview & Learning Objectives
- Review the burden of keratinocyte carcinomas (KCC)
- Recognize advances in risk stratification of patients with keratinocyte carcinoma
- Discuss recently approved therapeutic strategies in CSCC, including the use of Immune Checkpoint Inhibitors as primary treatment for advanced disease, as well as emerging strategies in the neo-adjuvant and adjuvant setting
- Review the recent evidence demonstrating activity of Immune Checkpoint Inhibitors for Basal Cell Carcinoma